High-dose definitive concomitant chemoradiotherapy in non-metastatic locally advanced esophageal cancer: Toxicity and outcome

Diseases of the Esophagus

Volumn 23, Issue 3, 2010, Pages 244-252

  Hurmuzlu, M ^a,b   Monge, O R ^a   Smaaland, R ^a   Viste, A ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

Author keywords

Combined modality therapy; Esophageal neoplasms; Radiotherapy dosage; Survival rate; Toxicity

Indexed keywords

CISPLATIN; DEXAMETHASONE; FLUOROURACIL; METOCLOPRAMIDE; ONDANSETRON; ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SPECIFIC SURVIVAL; DRUG MEGADOSE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGITIS; ESOPHAGUS CANCER; FEMALE; FOLLOW UP; HUMAN; INFECTION; LEUKOPENIA; MALE; METASTASIS; MULTIVARIATE ANALYSIS; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY; SEPTICEMIA; STOMATITIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; ADJUVANT THERAPY; CANCER STAGING; CARCINOMA; COHORT ANALYSIS; DISEASE FREE SURVIVAL; ESOPHAGUS TUMOR; MIDDLE AGED; MORTALITY; PATHOLOGY; RADIATION DOSE; SURVIVAL RATE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA; CISPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; RADIOTHERAPY, ADJUVANT; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 77957264625     PISSN: 11208694     EISSN: 14422050     Source Type: Journal    
DOI: 10.1111/j.1442-2050.2009.00999.x     Document Type: Article

References (33)

1. :Enzinger P C, Mayer R J. Esophageal cancer. N Engl J Med 2003; 349 (23): 2241-52.
2. Cooper J S, Guo M D, Herskovic A et al. Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group. JAMA 1999; 281 (17): 1623-7.
3. Al-Sarraf M, Martz K, Herskovic A et al. Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 1997; 15 (1): 277-84.
4. Herskovic A, Martz K, Al-Sarraf M et al. Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 1992; 326 (24): 1593-8.
5. Zhang Z, Liao Z, Jin J et al. Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy. Int J Radiat Oncol Biol Phys 2005; 61 (3): 656-64.
6. Seung S K, Smith J W, Molendyk J et al. Selective dose escalation of chemoradiotherapy for esophageal cancer: role of treatment intensification. Semin Oncol 2004; 31 (6 Suppl 18): 13-19.
7. Kleinberg L, Knisely J P, Heitmiller R et al. Mature survival results with preoperative cisplatin, protracted infusion 5-fluorouracil, and 44-Gy radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 2003; 56 (2): 328-34.
8. Tougeron D, Di Fiore F, Hamidou H, Rigal O, Paillot B, Michel P. Response to definitive chemoradiotherapy and survival in patients with an oesophageal adenocarcinoma versus squamous cell carcinoma: a matched-pair analysis. Oncology 2007; 73 (5-6): 328-34.
9. Sobin L H, Wittekind C, International Union against Cancer. TNM: Classification of Malignant Tumours, 6th edn. New York: Wiley-Liss, 2002.
10. Bowrey D J, Clark G W, Roberts S A et al. Serial endoscopic ultrasound in the assessment of response to chemoradiotherapy for carcinoma of the esophagus. J Gastrointest Surg 1999; 3 (5): 462-7.
11. Schneider P M, Metzger R, Schaefer H et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg 2008; 248 (6): 902-8.
12. National Cancer Institute. Available from URL: http://www.cancer.gov and search for CTCAE v 3.
13. Bedenne L, Michel P, Bouche O et al. Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. J Clin Oncol 2007;(10): 1160-8
14. Ishida K, Ando N, Yamamoto S, Ide H, Shinoda M. Phase II study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus: a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516). Jpn J Clin Oncol 2004; 34 (10): 615-19.
15. Minsky B D, Pajak T F, Ginsberg R J et al. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: high-dose versus standard-dose radiation therapy. J Clin Oncol 2002; 20 (5): 1167-74.
16. Sai H, Mitsumori M, Yamauchi C et al. Concurrent chemoradiotherapy for esophageal cancer: comparison between intermittent standard-dose cisplatin with 5-fluorouracil and daily low-dose cisplatin with continuous infusion of 5-fluorouracil. Int J Clin Oncol 2004; 9 (3): 149-53.
17. Sasamoto R, Sakai K, Inakoshi H et al. Long-term results of chemoradiotherapy for locally advanced esophageal cancer, using daily low-dose 5-fluorouracil and cis-diammine-dichloroplatinum (CDDP). Int J Clin Oncol 2007; 12 (1): 25-30.
18. Hryniuk W M, Goodyear M. The calculation of received dose intensity. J Clin Oncol 1990; 8 (12): 1935-7.
19. Liao Z, Zhang Z, Jin J et al. Esophagectomy after concurrent chemoradiotherapy improves locoregional control in clinical stage II or III esophageal cancer patients. Int J Radiat Oncol Biol Phys 2004; 60 (5): 1484-93.
20. Crosby T D, Brewster A E, Borley A et al. Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer 2004; 90 (1): 70-5.
21. Tougeron D, Di Fiore F, Thureau S et al. Safety and outcome of definitive chemoradiotherapy in elderly patients with oesophageal cancer. Br J Cancer 2008; 99 (10): 1586-92.
22. Di Fiore F, Lecleire S, Rigal O et al. Predictive factors of survival in patients treated with definitive chemoradiotherapy for squamous cell esophageal carcinoma. World J Gastroenterol 2006; 12 (26): 4185-90.
23. Adams R, Morgan M, Mukherjee S et al. A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network. Eur J Surg Oncol 2007; 33 (3): 307-13.
24. ButtonMR, Morgan C A, Croydon E S, Roberts S A, Crosby T D. Study to determine adequate margins in radiotherapy planning for esophageal carcinoma by detailing patterns of recurrence after definitive chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 73 (3): 818-23.
25. Geh J I, Crellin A M, Glynne-Jones R. Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br J Surg 2001; 88 (3): 338-56.
26. Bedford J L, Viviers L, Guzel Z, Childs P J, Webb S, Tait DM. A quantitative treatment planning study evaluating the potential of dose escalation in conformal radiotherapy of the oesophagus. Radiother Oncol 2000; 57 (2): 183-93.
27. Cunningham D, Starling N, Rao S et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008; 358 (1): 36-46.
28. Dank M, Zaluski J, BaroneCet al. Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction. Ann Oncol 2008; 19 (8): 1450-7.
29. Heath E I, Urba S, Marshall J, Piantadosi S, Forastiere A A. Phase II trial of docetaxel chemotherapy in patients with incurable adenocarcinoma of the esophagus. Invest New Drugs 2002; 20 (1): 95-9.
30. Di Fiore F, Lecleire S, Pop D et al. Baseline nutritional status is predictive of response to treatment and survival in patients treated by definitive chemoradiotherapy for a locally advanced esophageal cancer. Am J Gastroenterol 2007; 102 (11): 2557-63.
31. Stahl M, Stuschke M, Lehmann N et al. Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol 2005; 23 (10): 2310-17.
32. Ancona E, Ruol A, Santi S et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with resectable esophageal squamous cell carcinoma: final report of a randomized, controlled trial of preoperative chemotherapy versus surgery alone. Cancer 2001; 91 (11): 2165-74.
33. Portale G, Peters J H, Hsieh C C et al. Esophageal adenocarcinoma in patients < or = 50 years old: delayed diagnosis and advanced disease at presentation. Am Surg 2004; 70 (11): 954-8.